News
San Antonio Breast Cancer Symposium 2017

https://doi.org/10.1016/S1470-2045(17)30930-0Get rights and content

Section snippets

MONALEESA-2 trial

Debu Tripathy (University of Texas MD Anderson Cancer Center, Houston, TX, USA) and colleagues presented an interim analysis of the randomised, phase 3, MONALEESA-2 trial, the first trial investigating the addition of cyclin D1/CDK4/6 inhibitor ribociclib to standard hormone therapy in women with premenopausal or perimenopausal, hormone receptor–positive (HR-positive), HER2-negative advanced breast cancer. 672 patients were randomly assigned (1:1) to ribociclib (600 mg per day, 3-weeks on,

EMBRACA trial

Results from the open-label, randomised, phase 3 trial comparing talazoparib to standard chemotherapy in women with BRCA-positive metastatic breast cancer were presented. Jennifer Litton (MD Anderson Cancer Center, Houston, TX, USA) and colleagues randomly assigned (2:1) 431 patients with HER2-negative, BRCA-mutant, advanced breast cancerto talazoparib (1 mg per day) or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine). The primary endpoint was

SUCCESS study

Wolfgang Janni (University Hospital Ulm, Ulm, Germany) and colleagues presented results from the open-label, randomised, phase 3, SUCCESS study, investigating the extension of adjuvant bisphosphonate therapy in patients with women with high-risk early breast cancer. 2947 women were randomly assigned to either 5 years of zoledronate (4 mg every 3 months for 2 years, followed by 4 mg every 6 months for 3 years) or 2 years (4 mg every 3 months for 2 years) after completing adjuvant chemotherapy

Prognostic CTCs

Joseph A Sparano (Albert Einstein College of Medicine, New York, NY, USA) and colleagues presented data suggesting that circulating tumour cells (CTCs) are prognostic for late recurrence in operable stage II–III breast cancer. Their analysis included 547 patients with high-recurrence risk breast cancer who had participated in the phase 3 ECOG-ACRIN E5103 trial and who were still being followed up for 4·5–7·5 years after diagnosis. At a median follow-up of 1·8 years, there were 15 recurrences,

Lapatinib in HER2-positive breast cancer

Ian E Krop (Dana-Farber Cancer Institute, Boston, MA, USA) presented the findings of the randomised, phase 3, CALGB 40601 trial, showing that addition of lapatinib to a trastuzumab plus paclitaxel regimen significantly improved invasive disease-free survival in patients with HER2-positive breast cancer. 305 patients with stage II or III HER2-positive breast cancer were randomly assigned to either paclitaxel plus trastuzumab alone or the same combination plus lapatinib for 16 weeks before

References (0)

Cited by (0)

View full text